Question 1

What does Pharmalliance Consulting Ltd specialise in?

Accepted Answer

Pharmalliance Consulting Ltd specialises in contamination control, GMP compliance, and quality risk management for regulated life science industries. We support pharmaceutical, contract and cosmetic manufacturers in achieving regulatory compliance with EU Annex 1, FDA and EMA.

https://www.pharmalliance.ie/services

Question 2

Which industries benefit most from Pharmalliance's contamination control expertise?

Accepted Answer

We support sterile pharmaceutical manufacturing, ATMPs, cell and gene therapy, biologics, cosmetic companies and compounding pharmacies. Our contamination control strategies are tailored for high-risk GMP environments where sterility, pyrogen control, and regulatory compliance are critical.

Question 3

Does Pharmalliance offer support for FDA or EMA inspection readiness?

Accepted Answer

Yes, Pharmalliance offers inspection readiness services for FDA and EMA. We prepare your facility through mock audits, document reviews, and training, ensuring compliance with GMP, ICH Q9, and Annex 1 contamination control expectations.

Test your current Quality System maturity and receive an instant readiness score:

https://www.pharmalliance.ie/qmm

Question 4

How can Pharmalliance help pharmaceutical companies meet EU Annex 1 requirements?

Accepted Answer

Pharmalliance provides expert guidance on implementing EU GMP Annex 1 through gap assessments, CCS creation, environmental monitoring strategies, and personnel training. We ensure your sterile manufacturing operations align with regulatory expectations for contamination control and sterility assurance.

Evaluate your Annex 1 compliance instantly

https://www.pharmalliance.ie/evaluation

Question 5

What is a Contamination Control Strategy (CCS) and why is it critical in GMP environments?

Accepted Answer

A Contamination Control Strategy (CCS) is a documented plan that integrates all control measures to prevent microbial, particulate, and endotoxin contamination. Required by EU Annex 1, a robust CCS protects product quality and patient safety in pharmaceutical manufacturing.

https://www.pharmalliance.ie/prevent-pharmaceutical-contamination

Question 6

How do I develop a robust Contamination Control Strategy (CCS) for sterile manufacturing?

Accepted Answer

Pharmalliance guides you through a structured CCS creation process, including risk assessment (FMEA), facility mapping, microbial control evaluation, and aligning with PDA TR90 and EU Annex 1. Our contamination control experts ensure your CCS is holistic and GMP-compliant.

https://www.pharmalliance.ie/prevent-pharmaceutical-contamination

Question 7

What are the key elements of a contamination control program according to EU Annex 1?

Accepted Answer

Annex 1 outlines 16 core elements for a CCS, including facility and equipment design, utilities, personnel training, cleaning and disinfection, environmental monitoring, and quality risk management. Pharmalliance helps integrate all elements into a unified contamination control strategy.

https://www.pharmalliance.ie/prevent-pharmaceutical-contamination

Question 8

How does Pharmalliance support gap assessments against EU Annex 1 contamination control requirements?

Accepted Answer

Pharmalliance performs detailed gap assessments comparing your current practices to Annex 1 and PDA TR90 requirements. We identify missing CCS elements, define remediation plans, and support implementation.

https://www.pharmalliance.ie/facility-audits

Question 9

Why is environmental monitoring critical to aseptic processing compliance?

Accepted Answer

Environmental monitoring (EM) provides real-time feedback on contamination control in cleanrooms. Pharmalliance ensures EM programs align with Annex 1, including continuous monitoring in Grade A zones, trend analysis, and actionable microbial limits to support sterility assurance.

Instantly assess your Annex 1 compliance with our Annex 1 Evaluation Tool:

https://www.pharmalliance.ie/evaluation

Question 10

What is the difference between viable and non-viable contamination in GMP environments?

Accepted Answer

Viable contamination refers to living microorganisms, while non-viable refers to inert particles such as dust or fibers. Both types can affect sterile product integrity. Pharmalliance designs monitoring programs that detect and control both viable and non-viable contamination per GMP and ISO 14644-1 standards.

https://www.pharmalliance.ie/contaminationcontrol

Question 11

How can Pharmalliance assist in facility design reviews to prevent microbial contamination?

Accepted Answer

We review facility layouts, airflow design, material/personnel flows, and cleanroom classifications to minimize contamination risk. Our design input supports CCS goals and ensures compliance with EU GMP and ISO 14644.

https://www.pharmalliance.ie/prevent-pharmaceutical-contamination

Question 12

How often should we review and update our CCS document for GMP compliance?

Accepted Answer

EU Annex 1 mandates periodic review and updates of your CCS. Pharmalliance recommends annual reviews, or after any facility, process, or regulatory change. Regular updates ensure continuous improvement and alignment with evolving GMP expectations.

https://www.pharmalliance.ie/prevent-pharmaceutical-contamination

Question 13

What are the benefits of implementing a holistic CCS as per PDA TR90 guidance?

Accepted Answer

Implementing a holistic CCS per PDA TR90 improves contamination visibility, links QRM with quality systems, enhances decision making, and ensures compliance with Annex 1, improving patient safety and reducing recall risks.

https://www.pharmalliance.ie/prevent-pharmaceutical-contamination

Question 14

How do you measure the effectiveness of a contamination control strategy over time?

Accepted Answer

We use Key Performance Indicators (KPIs) such as EM trends, rejected batches, sterility test outcomes, and deviation rates to measure CCS effectiveness. Pharmalliance also supports CCS lifecycle review and continuous improvement.

https://www.pharmalliance.ie/prevent-pharmaceutical-contamination

Question 15

Can Pharmalliance help us design a Quality Risk Management (QRM) program aligned with ICH Q9 (R1)?

Accepted Answer

Yes, our consultants specialize in building QRM programs aligned with ICH Q9 (R1). We help you apply risk tools like FMEA and HACCP to assess microbial, particulate, and cross-contamination risks in sterile manufacturing.

https://www.pharmalliance.ie/qualitysystems

Question 16

What role does Pharmalliance play in contamination root cause investigations and CAPA development?

Accepted Answer

We provide expert root cause analysis and CAPA support for microbial, endotoxin, or particulate contamination events. Our structured approach integrates with your QMS to strengthen your contamination control lifecycle.

https://www.pharmalliance.ie/contaminationcontrol

Question 17

How can I access Pharmalliance’s contamination control training modules?

Accepted Answer

Pharmalliance’s CCS and GMP training is available online via our learning platform. It includes 35+ modules, downloadable templates, and expert videos, accessible on-demand for professionals in quality, production, and validation roles.

https://www.pharmalliance.ie/training-programs

Question 18

Do you offer on-site or virtual GMP training for manufacturing personnel?

Accepted Answer

Yes, Pharmalliance offers both on-site and virtual GMP training sessions tailored to your manufacturing environment. We cover Annex 1 updates, aseptic technique, and contamination control best practices for your facility.

https://www.pharmalliance.ie/training-programs

FREQUENTLY ASKED QUESTIONS